Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease
Information source: Nanfang Hospital of Southern Medical University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Nonalcoholic Fatty Liver Disease (NAFLD)
Intervention: Perindopril (Drug); Telmisartan (Drug); Amlodipine (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Nanfang Hospital of Southern Medical University Official(s) and/or principal investigator(s): Side Liu, MD,PhD, Principal Investigator, Affiliation: Department of Gastroenterology, Nanfang Hospital, Southern Medical University
Overall contact: Side Liu, MD,PhD, Phone: +86 020 61641537, Email: liuside2011@163.com
Summary
The aim of this current study was to assess the therapeutic effects of perindopril and
telmisartan for hypertensive patients with NAFLD and make comparison between the therapeutic
effects of these two kind of drugs.
This study is a randomized parallel control clinical trial which would be carried out in
Nanfang Hospital, Southern Medical University.
About one hundred and eighty patients would be randomly assigned to perindopril,telmisartan
and amlodipine three groups.
Clinical Details
Official title: Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Cap value of FibroScan (dB/m)
Secondary outcome: Angiotensin IIIL-18,IL-1β aminotransferase lipids HOMA-IR computed tomography value of liver
Detailed description:
Inclusion criteria:
18-70 years old patients who were diagnosed with mild-moderate hypertension and NAFLD; The
patients did not take ACEIs or ARBs drugs six weeks before the inclusion; Patients agreed to
participate in the trial and signed the informed consent.
Exclusion criteria:
There are no coexisting causes for chronic liver disease, such as viral,
alcoholic,drug-induced and autoimmune liver diseases; Patients with diabetes mellitus;
Patients with serious primary diseases; Patients with mental disorder or can not take the
medicine regularly; Pregnancy and nursing mothers; Allergic constitution or intolerance to
ACEIs or ARBs drugs. Outcome measures include Cap value of FibroScan,angiotensin
II,IL-18,IL-1β,aminotransferase,lipids and HOMA-IR.
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 18-70 years old patients who were diagnosed with mild-moderate hypertension and
NAFLD;
- The patients did not take ACEIs or ARBs drugs six weeks before the inclusion;
Patients agreed to participate in the trial and signed the informed consent.
Exclusion Criteria:
- There are no coexisting causes for chronic liver disease, such as viral,
alcoholic,drug-induced and autoimmune liver diseases;
- Patients with diabetes mellitus; Patients with serious primary diseases; Patients
with mental disorder or can not take the medicine regularly;
- Pregnancy and nursing mothers;
- Allergic constitution or intolerance to ACEIs or ARBs drugs.
Locations and Contacts
Side Liu, MD,PhD, Phone: +86 020 61641537, Email: liuside2011@163.com
Nanfang Hospital, Southern Medical University, GuangZhou, Guangdong 510515, China; Recruiting Yue Li, MD, Phone: +86-15975537291, Email: liyue_1989919@126.com Side Liu, MD.PhD, Principal Investigator Yue Li, MD, Sub-Investigator Xu Li, MD, Sub-Investigator Zelong Han, MD, Sub-Investigator Wen Xu, MM, Sub-Investigator Yubin Guo, MM, Sub-Investigator Feng Xiong, MD, Sub-Investigator
Additional Information
Starting date: August 2014
Last updated: August 8, 2014
|